Key Highlights
- Net loss of USD 3.42 million, against USD 5.41 million a year earlier.
- Per-share loss of USD 0.14, versus USD 0.25 in the prior-year period.
- Operating expenses totaled USD 3.44 million, against USD 5.47 million.
- Cash stood at USD 2.10 million on September 30.
Actuate's filing for the quarter to September 30, 2026 shows that Actuate Therapeutics (NASDAQ:ACTU) lost USD 3,420,649 in the third quarter, against USD 5,407,470 in the same quarter of 2025. The basic and diluted loss per share for common stockholders was USD 0.14, versus USD 0.25.
The weighted-average count of common shares outstanding was 24,222,586, up from 21,394,965 in the earlier quarter.
Where the Quarter's Costs Came From
Research and development expenses were USD 1,811,601, against USD 2,177,922, while general and administrative expenses were USD 1,627,486, against USD 3,294,456. Total operating expenses reached USD 3,439,087, against USD 5,472,378. In each period the loss from operations matched total operating expenses.
Interest income was USD 23,501, against USD 69,971, and net other income overall was USD 18,438, against USD 64,908. Share-based compensation came to USD 970,824, against USD 1,800,614.
Nine Months Set Against the Prior Period
Across the nine months ended September 30, 2026, the net loss was USD 13,913,033, against USD 17,673,899, and the loss per share was USD 0.58, against USD 0.88. Total operating expenses were USD 14,051,631, against USD 17,806,839.
Within that, Research and Development cost USD 6,443,670, against USD 8,163,046, and general and administrative expenses were USD 7,607,961, against USD 9,643,793. Interest income was USD 153,786, against USD 148,128, and share-based compensation totaled USD 3,667,982, against USD 4,504,986.
Cash, Assets and Liabilities at Quarter End
Cash and cash equivalents were USD 2,101,816, whereas the prior Balance Sheet date showed USD 13,159,423. Prepaid items and other current holdings were USD 546,246, against USD 483,996, while total current assets were USD 2,648,062, against USD 13,643,419.
Total assets were USD 3,218,781, against USD 14,035,910, and total liabilities were USD 4,027,747, against USD 6,111,907. Over the nine months, Operating Activities used USD 12,373,256 of cash, against USD 15,470,210.
Financing Terms Set Out in the Filing
On November 28, 2025, the company signed a sales agreement of the at-the-market type for issuing shares. It allows Actuate to issue and sell up to USD 100 million of common stock through two sales agents, whose commission is capped at 3.0% of gross proceeds. Actuate alone decides when to sell, using any approach Rule 415 treats as at-the-market, and the agents hold customary indemnification rights.
The filing also refers to a committed Equity Facility dated March 27, 2025. Interest expense was USD 5,063 in both the 2026 and 2025 third quarters, and USD 15,188 over the nine months. Deferred offering costs sit within non-current assets.






Please wait processing your request...